Trial Profile
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary) ; Trastuzumab (Primary) ; Antineoplastics
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms monarcHER
- Sponsors Eli Lilly and Company
- 18 Mar 2024 Status changed from active, no longer recruiting to completed.
- 10 Jan 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 22 Dec 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.